Table 1.
Baseline demographic and patient characteristics.
| Characteristic | Arm B | Arm C | Arm D |
|---|---|---|---|
| Atezo + IFNα | Atezo + PEG-IFNα | Atezo + PEG-IFNα + Bev | |
| (n = 65) | (n = 6) | (n = 45) | |
| Tumor type, n (%) | |||
| RCC | 50 (76.9) | 6 (100) | 21 (46.7) |
| Melanoma | 14 (21.5) | 0 | 3 (6.7) |
| CRC | 0 | 0 | 14 (31.1) |
| NSCLC | 1 (1.5) | 0 | 7 (15.6) |
| Age group, n (%) | |||
| <65 y | 39 (60.0) | 2 (33.3) | 30 (66.7) |
| ≥65 y | 26 (40.0) | 4 (66.7) | 15 (33.3) |
| Sex, n (%) | |||
| Male | 56 (86.2) | 6 (100) | 27 (60.0) |
| Female | 9 (13.8) | 0 | 18 (40.0) |
| Race, n (%) | |||
| Black or African American | 3 (4.6) | 0 | 7 (15.6) |
| White | 60 (92.3) | 6 (100) | 32 (71.1) |
| Asian | 1 (1.5) | 0 | 4 (8.9) |
| Unknown | 1 (1.5) | 0 | 2 (4.4) |
| ECOG performance status, n (%) | |||
| 0 | 49 (75.4) | 3 (50.0) | 32 (72.7) a |
| 1 | 16 (24.6) | 3 (50.0) | 12 (27.3) a |
| Prior systemic therapy, n (%) | |||
| Yes | 55 (84.6) | 6 (100) | 30 (66.7) |
| No | 10 (15.4) | 0 | 15 (33.3) |
| Prior cancer surgery, n (%) | |||
| Yes | 61 (93.8) | 6 (100) | 26 (57.8) |
| No | 4 (6.2) | 0 | 19 (42.2) |
| Prior radiotherapy, n (%) | |||
| Yes | 36 (55.4) | 3 (50.0) | 16 (35.6) |
| No | 29 (44.6) | 3 (50.0) | 29 (64.4) |
| PD-L1 IC score, n (%) b | |||
| IC0 | 30 (46.2) | 4 (66.7) | 27 (60.0) |
| IC1/2/3 | 26 (40.0) | 1 (16.7) | 3 (6.7) |
| Unknown | 9 (13.8) | 1 (16.7) | 15 (33.3) |
| PD-L1 TC score, n (%) c | |||
| TC0 | 51 (78.5) | 5 (83.3) | 28 (62.2) |
| TC1/2/3 | 5 (7.7) | 0 | 2 (4.4) |
| Unknown | 9 (13.8) | 1 (16.7) | 15 (33.3) |
atezo, atezolizumab; bev, bevacizumab; CRC, colorectal carcinoma; ECOG, Eastern Cooperative Oncology Group; IC, tumor-infiltrating immune cell; IFNα, interferon-α; NSCLC, non-small cell lung cancer; PEG-IFNα, polyethylene glycol interferon-; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma; TC, tumor cell. a Baseline ECOG PS was unavailable for 1 patient in Arm D. b Using VENTANA SP142 IHC assay (Ventana Medical Systems): IC0 was ≤ 1% PD-L1 expression on IC; IC1 was ≥ 1% and was <5% PD-L1 expression on IC; IC2 was ≥5% and was <10% PD-L1 expression on IC; IC3 was ≥ 10% PD-L1 expression on IC. c Using VENTANA SP142 IHC assay (Ventana Medical Systems): TC0 was < 1% PD-L1 expression on TC; TC1 was ≥ 1% and was <5% PD-L1 expression on TC; TC2 was ≥ 5% and was <50% PD-L1 expression on TC; TC3 was ≥ 50% PD-L1 expression on TC.